APL-2

pegylated C3 inhibitor · Apellis Pharmaceuticals, Inc.

Drug timelines are a Plus or Pro feature.

6 regulatory and trial events tracked for APL-2, covering 2022-03-25 to 2026-03-23. Get the full timeline:

Most recent: Clinical Trial Update: APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion [Phase 2]

See pricing